Menu
News
Recent news
NucleoCapture is designed to selectively remove neutrophil extracellular traps (NETs) from the bloodstream. In sepsis, where progressive organ dysfunction remains a major driver of mortality, NUC-CAP will evaluate whether removing them translates into clinical benefit.
The multinational, randomized pivotal study is expected to enroll up to 350 patients with sepsis and respiratory failure across the United States and Europe. Patients will be randomized 1:1 to standard of care alone or standard of care with NucleoCapture, with a primary effectiveness endpoint comprising all-cause mortality and organ support-free days through Day 28.
September 16, 2026
The Proposed Transaction is expected to create a Nasdaq-listed, multi-indication clinical-stage company focused on a single high-impact therapeutic target: neutrophil extracellular traps, or NETs. By combining two complementary approaches to targeting NETs, NucleoCapture®, which is designed to physically remove NETs from circulation, and Xenetic’s DNase technology, which is designed to enzymatically degrade NETs in tissue, the combined company is expected to have a differentiated therapeutic platform capable of targeting NET-driven disease through two distinct modalities.
December 11, 2025
Santersus AG today announced two senior leadership appointments that strengthen the company’s executive and governance capabilities as it advances its NucleoCapture™ toward pivotal clinical development.
Santersus AG today announced the successful completion of its Series A financing, led by Norcliffe, a UK life sciences fund with participation from Terumo Ventures. The financing will support the advancement of Santersus’ NucleoCapture™ into pivotal clinical development while accelerating progress across Santersus’ broader pipeline.